MuReva’s lightguide technology represents a significant advancement in supportive cancer care, offering both therapeutic relief and preventive benefits for patients at risk of OM.
This technology is being introduced as part of our broader efforts to support the integration of innovative, patient-centered solutions into modern oncology care infrastructure in India..
Photobiomodulation: Pathway to Wound Healing
MuReva introduces a non-invasive, daily 10-minute treatment that integrates smoothly into clinical workflows. Based on photobiomodulation therapy, the system offers:
Patient comfort: a soft, flexible illuminated mouthpiece
Controlled light delivery: simultaneous and precise dosing to all OM-susceptible areas, including the back of the throat
Proven safety: light transmission via fiber-optic cable without generating heat
Technology protected by 40 global patents, including 6 issued in the United States
Single-patient device supporting individualized therapy and infection control
Currently, OM is primarily managed with palliative care, leaving a significant gap in effective and preventive solutions. The condition often results in painful ulcers, difficulty swallowing, treatment delays, and a notable increase in healthcare costs due to ER visits and feeding tube insertions.
Oral mucositis is a common and debilitating complication of chemotherapy, radiotherapy, and immunotherapy, affecting:
- Up to 60% of patients on standard-dose chemotherapy
- Approximately 30% of patients undergoing radiotherapy
We are pleased to highlight MuReva, a groundbreaking phototherapy system designed to address one of the most challenging side effects in oncology care — oral mucositis (OM).